Standard 30-minute Monitoring Time and Less Intensive Pre-medications is Safe in Patients Treated With Subcutaneous Daratumumab for Multiple Myeloma and Light Chain Amyloidosis.
作者信息
Hughes David M, Henshaw Lynnette, Blevins Frances, Edwards Camille, Lerner Adam, Sloan John Mark, Sanchorawala Vaishali
机构信息
Department of Pharmacy, Boston Medical Center, Boston, MA; School of Medicine, Boston University, Boston, MA; Department of Hematology and Oncology, Boston Medical Center, Boston, MA.
Department of Pharmacy, Boston Medical Center, Boston, MA; Department of Hematology and Oncology, Boston Medical Center, Boston, MA.
出版信息
Clin Lymphoma Myeloma Leuk. 2022 Aug;22(8):566-568. doi: 10.1016/j.clml.2022.03.003. Epub 2022 Mar 9.
PMID:35367193
Abstract
摘要
Zotero 插件